NCT01884688View on ClinicalTrials.gov

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Asymptomatic Multiple Myeloma
Interventions
DRUG

ENK Cell Infusion

Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU

Trial Locations (1)

72205

University of Arkansas for Medical Science, Little Rock

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Arkansas

OTHER

NCT01884688 - UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | Biotech Hunter | Biotech Hunter